Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease
https://doi.org/10.47360/1995-4484-2020-428-436
Abstract
Non-infectious uveitis is the leading and insufficiently studied cause of irreversible decline in visual functions in patients with immune-mediated inflammatory rheumatic disease (IMIRDs). A multidisciplinary approach to the diagnosis and treatment of uveitis in patients with IMIRDs, involving close collaboration of rheumatologists and ophthalmologists, is the key factor for achieving favorable clinical outcomes. This article sheds light on current clinical, differential diagnostic and therapeutic challenges related to non-infectious uveitis in IMIDs-patients, with specific emphasis on state-of-the art approaches to therapy.
About the Authors
T. A. Lisitsyna
VA Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
Z. S. Alekberova
VA Nasonova Research Institute of Rheumatology
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
G. A. Davydova
Helmholtz Moscow Research Institute of Eye Diseases, Ministry of Health of Russia
Russian Federation
14/19 SadovayaChernogryazskaya St., Moscow 105064
Russian Federation
14/19 SadovayaChernogryazskaya St., Moscow 105064
T. M. Reshetnyak
VA Nasonova Research Institute of Rheumatology
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
L. A. Katargina
Helmholtz Moscow Research Institute of Eye Diseases, Ministry of Health of Russia
Russian Federation
14/19 SadovayaChernogryazskaya St., Moscow 105064
Russian Federation
14/19 SadovayaChernogryazskaya St., Moscow 105064
E. L. Nasonov
VA Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
34A Kashirskoe Shosse, Moscow 115522
8, Trubetskaya St., Build 2 Moscow 119991
References
1. Non-infectious uveitis. Clinical guidelines LLC “Association of Ophthalmologists”, LLC “Society of Ophthalmologists of Russia”2019 г. http://avo-portal.ru/doc/fkr/development/item/343-neinfektsionnye-uveity; https://oor.ru/vracham/klrek/proekt-klinicheskikh-rekomendatsiy-neinfektsionnye-uveity-dlya-obsuzhdeniya/ (in Russ)
2. Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum 2019; 49(3): 438-445 doi: 10.1016/j.semarthrit.2019.06.004
3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardiza-tion of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057
4. Deschenes J, Murray P, Rao N, Nussenblatt R. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis. Ocular Immunology and Inflammation. 2008; 16(1-2): 1-2. doi:10.1080/09273940801899822
5. Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm. 2018; 26 (1): 2-16. doi:10.1080/09273948.2016.1196713
6. Chora I, Borges T, Dias C, Ourique C, Vilaça J, et al. Clinical Management of Uveitis in Systemic Rheumatic Autoimmune Diseases in Adults. Autoimmun Infec Dis. 2015; 1 (1): doi http://dx.doi.org/10.16966/2470-1025.104
7. Juanola X, Loza Santamaria E, Cordero-Coma M. Sentinel Working Group. Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL Interdisciplinary Collaborative Project. Ophthalmology. 2016; 123: 1632–6 https://doi.org/10.1016/j.ophtha.2016.03.010
8. Forrester JV, Kuffova L, Dick AD. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am J Ophthalmology. 2018;189:77-85. doi:10.1016/j.ajo.2018.02.019
9. Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2020;100866. doi:10.1016/j.preteyeres.2020.100866
10. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018; 125 (5): 757–773. doi:10.1016/j.ophtha.2017.11.017
11. Valenzuela RA, Flores I, Urrutia B, et al. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. Front Pharmacol. 2020;11:655. Published 2020 May 8. doi:10.3389/fphar.2020.00655
12. Choi J, Hawley DP, Ashworth J, Edelsten C, Bossuyt ASAM. An update on the modern management of paediatric uveitis. Br J Ophthalmol. 2019;103(12):1685-1689. doi:10.1136/bjophthalmol-2019-314212
13. Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477-490. doi:10.1080/14712598.2019.1595578
14. Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, Do DV, Nguyen QD. New therapies in development for the management of non-infectious uveitis: A review. Clin. Experiment. Ophthalmol. 2019; 47: 396–417. doi: 10.1111/ceo.13511
15. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008; 15 (1): 47-55 doi: 10.1080/09286580701585892
16. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011; 16 (2): 309-322. doi: 10.1517/14728214.2011.537824.
17. Schultz C. Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis. 2013; 5: 5-10. doi: 10.4137/OED.S7995
18. Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and MetaAnalysis of Randomized Controlled Trials. Front Med (Lausanne). 2019;6:104. doi:10.3389/fmed.2019.00104
19. Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005-2016. doi:10.2147/DDDT.S160431
20. Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138-150. doi:10.1097/ICU.0000000000000562
21. Ahmed A, Foster CS. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis. Ophthalmic Res. 2019;61(1):44-50. doi:10.1159/000486791
22. Urruticoechea-Arana A, Cobo-Ibáñez T, Villaverde-García V, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review. Rheumatol Int. 2019;39(1):47-58. doi:10.1007/s00296-018-4193-z
23. Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17. doi:10.1186/s12348- 019-0182-y
24. Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017;183:71-80. doi:10.1016/j.ajo.2017.08.019
25. Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study. Ophthalmology. 2019;126(3):428-437. doi:10.1016/j.ophtha.2018.09.044
26. Dick AD, Tugal-Tutkun l, Foster S, Zierhut M, Liew SHM, Bezlyak V, Androudi S. Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology. 2013; 120: 777-787 https://doi.org/10.1016/j.ophtha.2012.09.040
27. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73-84. doi:10.1016/S0140-6736(16)31591-4
28. Molto A, Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2018;32(3):357-368. doi:10.1016/j.berh.2019.02.010
29. Rudwaleit M, Landewe R, van der Heijde D, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-83. doi: 10.1136/ard.2009.1082335
30. Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spon-dyloarthritis in general. Ann Rheum Dis. 201; 70 (1): 25-31. doi: 10.1136/ard.2010.133645
31. Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):802- 825. doi:10.1016/j.berh.2016.10.007
32. Godzenko AA, Bochkova AG, Rumyantseva OA, et al. Progression and outcomes of uveitis in patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2014; 52(5): 520–525. (In Russ.). doi: 10.14412/1995-4484-2014-520-525.
33. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi:10.1016/j.berh.2018.08.002
34. Mitulescu TC, Trandafir M, Dimăncescu MG, et al. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy? Rom J Ophthalmol. 2018;62(2):114-122
35. Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5): e12527. doi: 10.1111/dth.12527
36. Beketova TV. Systemic vasculitis. Russian clinical guidelines. Rheumatology. ed. E.L. Nasonov. M.: GEOTAR-Media, 2017. С.180–205. (in Russ)
37. Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):3- 20. doi:10.1016/j.berh.2018.10.003
38. Tugal-Tutkun I. Systemic vasculitis and the eye. Curr Opin Rheumatol. 2017;29(1):24-32. doi:10.1097/BOR.0000000000000345
39. Lisitsyna TA, Alekberova ZS, Goloeva RG, Davydova GA. Behcet’s disease: clinical manifestations, current principles of diagnosis and therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019; 57(5): 553-563 (In Russ.). doi: 10.14412/1995-4484-2019-553-563
40. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view [published correction appears in Nat Rev Rheumatol. 2018 Jan 24;14 (2):119]. Nat Rev Rheumatol. 2018;14(2):107-119. doi:10.1038/nrrheum.2017.208
41. Ksiaa I, Abroug N, Kechida M, et al. Eye and Behçet’s disease. J Fr Ophtalmol. 2019;42(4):e133-e146. doi:10.1016/j.jfo.2019.02.002
42. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225
43. Lisitsyna TA, Alekberova ZS, Goloeva RG. New guidelines for the management of patients with Behcet’s disease/syndrome (EULAR, 2018). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019; 57(2):133-141 (In Russ.) doi: 10.14412/1995-4484-2019-133-141
44. Uke P, Gorodkin R, Beare N. Biologic therapy for Behçet’s uveitis: a systematic review. Br J Ophthalmol. 2020;104(8):1045-1051. doi:10.1136/bjophthalmol-2019-314154
45. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. Ann Intern Med. 2008; 149 (4):284-286. doi: 10.7326/0003-4819-149-4-200808190-00018
46. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juve-nile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012; 71(9): 1589-1591. doi: 10.1136/annrheumdis-2012-201383
47. Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet’s disease. Clin Exp Rheumatol. 2017; 35 (6 suppl 108):130-131
48. Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018; 25:1-11. doi: 10.1080/09273948.2017.1421233
49. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8
50. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-2149. doi:10.1016/S0140-6736(11)60244-4
51. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi:10.1016/j.clim.2019.108322
52. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. doi:10.1186/s12969-018-0255-8
53. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107-1117. doi:10.1136/annrheumdis-2018-213131
54. Katargina LA, Brzhesky BB, Guseva Mr, Denisova EV, Drozdova EA, Zhukova OV, Nikishina IP, Starikova AV. The federal clinical guidelines on «The diagnostics and treatment of uveitis associated with juvenile idiopathic arthritis» Russian Pediatric Ophthalmology. 2016; 11(2): 102-11 (In Russ.) doi: 10.18821/1993-1859-2016-11-2-102-111
55. Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, et al. Update of the evidence based, interdisciplinary guideline for antiinflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2019; 49: 43-55. https://doi.org/10.1016/j.semarthrit.2018.11.004
56. Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2020;58(1):5-14. (In Russ.). doi:10.14412/1995-4484-2020-5-14
57. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi:10.1016/S0140-6736(19)30546-X
58. Cunningham ET, Tabbara KF, Zierhut M. Systemic Lupus Erythematosus and the Eye. Ocul Immunol Inflamm. 2018;26(8):1143-1145. doi:10.1080/09273948.2018.1539589
59. Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun. 2020;109:102421. doi:10.1016/j. jaut.2020.102421
60. Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V. Systemic autoinflammatory diseases: Clinical state of the art. Best Pract Res Clin Rheumatol. 2020;101529. doi:10.1016/j.berh.2020.101529
61. Salugina SO, Kuzmina NN, Fedorov ES. Auto-inflammatory syndromes – a «new» multidisciplinary problem in pediatrics and rheumatology. Pediatria= Pediatrics. 2012; 91 (5): 120-132 (In Russ.)
62. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2019;206:23-32. doi:10.1016/j.clim.2018.10.016
Review
For citations:
Lisitsyna T.A., Alekberova Z.S., Davydova G.A., Reshetnyak T.M., Katargina L.A., Nasonov E.L. Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease. Rheumatology Science and Practice. 2020;58(4):428-436. (In Russ.) https://doi.org/10.47360/1995-4484-2020-428-436
Views:
970
Email this article 